<p>3Chopt Investment Partners LLC 在最近向證券交易委員會（SEC）提交的 13F 表格中表示，在第三季度將其在百時美施貴寶公司（NYSE:BMY - 免費報告）的持股減少了 57.9%。該公司在季度內出售了 36,326 股後，持有 26,460 股該生物製藥公司的股票。3Chopt Investment Partners LLC 在百時美施貴寶的持股在最近的報告期末價值為 1,193,000 美元。</p>
<p>獲取 <strong>百時美施貴寶</strong> 的提醒：</p>
<ul>
<li>為什麼 GRAIL 股票可能成為生物技術的下一個重大突破</li>
</ul>
<p>其他機構投資者和對沖基金最近也對該公司的持股進行了調整。新英格蘭資產管理公司在第一季度將其在百時美施貴寶的持股增加了 0.8%。新英格蘭資產管理公司目前持有 39,476 股該生物製藥公司的股票，價值 2,408,000 美元，此前在該期間內又增持了 305 股。英聯邦退休投資公司在第二季度將其在百時美施貴寶的股份增加了 24.6%。英聯邦退休投資公司目前持有 59,183 股該生物製藥公司的股票，價值 2,740,000 美元，此前在該期間內又購買了 11,690 股。挪威銀行在第二季度購買了百時美施貴寶的新股份，價值 1,554,154,000 美元。財富四分之一公司在第二季度將其在百時美施貴寶的股份增加了 42.6%。財富四分之一公司目前持有 25,443 股該生物製藥公司的股票，價值 1,178,000 美元，此前在該期間內又增持了 7,603 股。最後，Sound View Wealth Advisors Group LLC 在第二季度將其在百時美施貴寶的持股增加了 438.0%。Sound View Wealth Advisors Group LLC 目前持有 307,849 股該生物製藥公司的股票，價值 14,250,000 美元，此前在上個季度又增持了 250,624 股。機構投資者持有該公司 76.41% 的股票。</p>
<h2>分析師設定新目標價</h2>
<p>幾位股票研究分析師對 BMY 股票發佈了報告。高盛集團在 12 月 2 日的研究報告中重申了 “中性” 評級，並將百時美施貴寶的目標價上調至 57.00 美元（此前為 51.00 美元）。滙豐銀行在 12 月 10 日的報告中重申了 “持有” 評級，並將百時美施貴寶的目標價設定為 53.00 美元。摩根士丹利在 12 月 12 日的報告中重申了 “減持” 評級，並將百時美施貴寶的目標價上調至 37.00 美元（此前為 36.00 美元）。古根海姆在 12 月 23 日的報告中重申了對百時美施貴寶的 “買入” 評級。最後，桑福德·C·伯恩斯坦在 11 月 3 日的研究報告中重申了對百時美施貴寶的 “市場表現” 評級。六位投資分析師對該股票給予了買入評級，十四位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “持有”，平均目標價為 54.62 美元。</p>
<ul>
<li>不要被反彈所迷惑：市場風暴尚未結束</li>
</ul>
<p><strong>閲讀我們對百時美施貴寶的最新分析</strong></p>
<h2>百時美施貴寶股票上漲 0.2%</h2>
<p>NYSE:BMY 週三開盤價為 54.22 美元。該公司的流動比率為 1.27，速動比率為 1.17，債務與股本比率為 2.39。百時美施貴寶公司的 12 個月低點為 42.52 美元，12 個月高點為 63.33 美元。該公司的市值為 1,103.8 億美元，市盈率為 18.32，市盈增長比率為 8.28，貝塔值為 0.29。該公司的 50 日移動平均線為 49.23 美元，200 日移動平均線為 47.39 美元。</p>
<ul>
<li>MarketBeat 週迴顧 – 02/03 - 02/07</li>
</ul>
<p>百時美施貴寶（NYSE:BMY - 獲取免費報告）最近一次發佈季度財報是在 10 月 30 日，生物製藥公司報告該季度每股收益為 1.63 美元，超出市場共識預期的 1.52 美元，超出幅度為 0.11 美元。百時美施貴寶的股本回報率為 76.53%，淨利潤率為 12.57%。該季度的營業收入為 122.2 億美元，而市場共識預期為 117.5 億美元。在去年同期，該公司的每股收益為 1.80 美元。該公司的季度收入較去年同期增長了 2.8%。百時美施貴寶已將其 2025 財年的指導目標設定為 6.400-6.600 美元每股收益。分析師預計百時美施貴寶公司今年將發佈 6.74 美元的每股收益。</p>
<h2>百時美施貴寶增加股息</h2>
<p>該公司最近還披露了季度股息，將於 2 月 2 日（星期一）支付。1 月 2 日的股東將獲得 0.63 美元的股息。除息日為 1 月 2 日。這比百時美施貴寶之前的季度股息 0.62 美元有所增加。這相當於每年 2.52 美元的股息，股息收益率為 4.6%。百時美施貴寶的股息支付比率（DPR）目前為 83.78%。</p>
<h2>百時美施貴寶簡介</h2>
<p>（免費報告）</p>
<p>百時美施貴寶是一家全球生物製藥公司，總部位於新澤西州普林斯頓，專注於發現、開發和提供針對嚴重疾病的藥物。該公司的核心業務包括研究與開發、臨牀開發、製造和商業化多個治療領域的處方藥。BMS 專注於通過小分子和生物製劑推進腫瘤學、血液學、免疫學、心血管疾病和特殊領域的治療。</p>
<p>BMS 的市場產品組合和後期管線反映出對癌症和免疫介導疾病的強烈關注。</p>
<h2>閲讀更多</h2>
<ul>
<li>我們更看好的五隻股票，勝過百時美施貴寶</li>
<li>請勿刪除，立即閲讀</li>
<li>崩盤已經開始（大多數人還未察覺）</li>
<li>警報：在 2026 年 1 月之前拋售這五隻股票！</li>
<li>[毫無疑問的黃金投資]：“給我看看更好的投資。”</li>
<li>投資者警報：微型 “3 美元人工智能奇蹟股票” 即將騰飛</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在百時美施貴寶嗎？</h2>
<p>在考慮百時美施貴寶之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場察覺之前...而百時美施貴寶並不在名單上。</p>
<p>雖然百時美施貴寶目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

百時美施貴寶

<p>3Chopt Investment Partners LLC 在第三季度將其在百時美施貴寶公司（NYSE:BMY）的持股減少了 57.9%，出售了 36,326 股，目前持有 26,460 股，市值為 119 萬美元。其他機構投資者也調整了他們的持倉，新英格蘭資產管理公司和聯邦退休投資公司顯著增加了持股。分析師對 BMY 的評級不一，平均目標價為 54.62 美元。該股票開盤價為 54.22 美元，略微上漲 0.2%。百時美施貴寶報告了強勁的季度收益，超出預期，每股收益為 1.63 美元，營收為 122.2 億美元</p>

<p>3Chopt Investment Partners LLC cut its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 57.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,460 shares of the biopharmaceutical company's stock after selling 36,326 shares during the quarter. 3Chopt Investment Partners LLC's holdings in Bristol Myers Squibb were worth $1,193,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>3Chopt Investment Partners LLC 在最近向證券交易委員會（SEC）提交的 13F 表格中表示，在第三季度將其在百時美施貴寶公司（NYSE:BMY - 免費報告）的持股減少了 57.9%。該公司在季度內出售了 36,326 股後，持有 26,460 股該生物製藥公司的股票。3Chopt Investment Partners LLC 在百時美施貴寶的持股在最近的報告期末價值為 1,193,000 美元。</p>
</div><p>Get <strong>Bristol Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>百時美施貴寶</strong> 的提醒：</p>
</div><ul>
<li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼 GRAIL 股票可能成為生物技術的下一個重大突破</li>
</ul>
</div><p>Other institutional investors and hedge funds also recently made changes to their positions in the company. New England Asset Management Inc. boosted its holdings in Bristol Myers Squibb by 0.8% during the 1st quarter. New England Asset Management Inc. now owns 39,476 shares of the biopharmaceutical company's stock valued at $2,408,000 after acquiring an additional 305 shares during the period. Commonwealth Retirement Investments LLC increased its stake in Bristol Myers Squibb by 24.6% in the second quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company's stock worth $2,740,000 after purchasing an additional 11,690 shares during the period. Norges Bank bought a new stake in shares of Bristol Myers Squibb during the second quarter worth $1,554,154,000. Wealth Quarterback LLC boosted its stake in shares of Bristol Myers Squibb by 42.6% during the second quarter. Wealth Quarterback LLC now owns 25,443 shares of the biopharmaceutical company's stock valued at $1,178,000 after purchasing an additional 7,603 shares during the period. Finally, Sound View Wealth Advisors Group LLC grew its holdings in shares of Bristol Myers Squibb by 438.0% in the second quarter. Sound View Wealth Advisors Group LLC now owns 307,849 shares of the biopharmaceutical company's stock worth $14,250,000 after purchasing an additional 250,624 shares during the last quarter. Institutional investors own 76.41% of the company's stock.</p>
<div class="lb-trans"><p>其他機構投資者和對沖基金最近也對該公司的持股進行了調整。新英格蘭資產管理公司在第一季度將其在百時美施貴寶的持股增加了 0.8%。新英格蘭資產管理公司目前持有 39,476 股該生物製藥公司的股票，價值 2,408,000 美元，此前在該期間內又增持了 305 股。英聯邦退休投資公司在第二季度將其在百時美施貴寶的股份增加了 24.6%。英聯邦退休投資公司目前持有 59,183 股該生物製藥公司的股票，價值 2,740,000 美元，此前在該期間內又購買了 11,690 股。挪威銀行在第二季度購買了百時美施貴寶的新股份，價值 1,554,154,000 美元。財富四分之一公司在第二季度將其在百時美施貴寶的股份增加了 42.6%。財富四分之一公司目前持有 25,443 股該生物製藥公司的股票，價值 1,178,000 美元，此前在該期間內又增持了 7,603 股。最後，Sound View Wealth Advisors Group LLC 在第二季度將其在百時美施貴寶的持股增加了 438.0%。Sound View Wealth Advisors Group LLC 目前持有 307,849 股該生物製藥公司的股票，價值 14,250,000 美元，此前在上個季度又增持了 250,624 股。機構投資者持有該公司 76.41% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Several equities research analysts have issued reports on BMY shares. The Goldman Sachs Group reissued a &#34;neutral&#34; rating and issued a $57.00 price objective (up from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. HSBC reiterated a &#34;hold&#34; rating and issued a $53.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, December 10th. Morgan Stanley restated an &#34;underweight&#34; rating and set a $37.00 price objective (up from $36.00) on shares of Bristol Myers Squibb in a report on Friday, December 12th. Guggenheim reiterated a &#34;buy&#34; rating on shares of Bristol Myers Squibb in a report on Tuesday, December 23rd. Finally, Sanford C. Bernstein reissued a &#34;market perform&#34; rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Six investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Hold&#34; and an average target price of $54.62.</p>
<div class="lb-trans"><p>幾位股票研究分析師對 BMY 股票發佈了報告。高盛集團在 12 月 2 日的研究報告中重申了 “中性” 評級，並將百時美施貴寶的目標價上調至 57.00 美元（此前為 51.00 美元）。滙豐銀行在 12 月 10 日的報告中重申了 “持有” 評級，並將百時美施貴寶的目標價設定為 53.00 美元。摩根士丹利在 12 月 12 日的報告中重申了 “減持” 評級，並將百時美施貴寶的目標價上調至 37.00 美元（此前為 36.00 美元）。古根海姆在 12 月 23 日的報告中重申了對百時美施貴寶的 “買入” 評級。最後，桑福德·C·伯恩斯坦在 11 月 3 日的研究報告中重申了對百時美施貴寶的 “市場表現” 評級。六位投資分析師對該股票給予了買入評級，十四位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “持有”，平均目標價為 54.62 美元。</p>
</div><ul>
<li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>不要被反彈所迷惑：市場風暴尚未結束</li>
</ul>
</div><p><strong>Read Our Latest Analysis on Bristol Myers Squibb</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對百時美施貴寶的最新分析</strong></p>
</div><h2>Bristol Myers Squibb Stock Up 0.2%</h2>
<div class="lb-trans"><h2>百時美施貴寶股票上漲 0.2%</h2>
</div><p>NYSE:BMY opened at $54.22 on Wednesday. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33. The company has a market cap of $110.38 billion, a PE ratio of 18.32, a P/E/G ratio of 8.28 and a beta of 0.29. The company's 50 day moving average is $49.23 and its two-hundred day moving average is $47.39.</p>
<div class="lb-trans"><p>NYSE:BMY 週三開盤價為 54.22 美元。該公司的流動比率為 1.27，速動比率為 1.17，債務與股本比率為 2.39。百時美施貴寶公司的 12 個月低點為 42.52 美元，12 個月高點為 63.33 美元。該公司的市值為 1,103.8 億美元，市盈率為 18.32，市盈增長比率為 8.28，貝塔值為 0.29。該公司的 50 日移動平均線為 49.23 美元，200 日移動平均線為 47.39 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 02/03 - 02/07</li>
</ul>
</div><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The business had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.75 billion. During the same quarter in the previous year, the business earned $1.80 EPS. The company's quarterly revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.</p>
<div class="lb-trans"><p>百時美施貴寶（NYSE:BMY - 獲取免費報告）最近一次發佈季度財報是在 10 月 30 日，生物製藥公司報告該季度每股收益為 1.63 美元，超出市場共識預期的 1.52 美元，超出幅度為 0.11 美元。百時美施貴寶的股本回報率為 76.53%，淨利潤率為 12.57%。該季度的營業收入為 122.2 億美元，而市場共識預期為 117.5 億美元。在去年同期，該公司的每股收益為 1.80 美元。該公司的季度收入較去年同期增長了 2.8%。百時美施貴寶已將其 2025 財年的指導目標設定為 6.400-6.600 美元每股收益。分析師預計百時美施貴寶公司今年將發佈 6.74 美元的每股收益。</p>
</div><h2>Bristol Myers Squibb Increases Dividend</h2>
<div class="lb-trans"><h2>百時美施貴寶增加股息</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be paid a $0.63 dividend. The ex-dividend date is Friday, January 2nd. This is an increase from Bristol Myers Squibb's previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.6%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 83.78%.</p>
<div class="lb-trans"><p>該公司最近還披露了季度股息，將於 2 月 2 日（星期一）支付。1 月 2 日的股東將獲得 0.63 美元的股息。除息日為 1 月 2 日。這比百時美施貴寶之前的季度股息 0.62 美元有所增加。這相當於每年 2.52 美元的股息，股息收益率為 4.6%。百時美施貴寶的股息支付比率（DPR）目前為 83.78%。</p>
</div><h2>Bristol Myers Squibb Profile</h2>
<div class="lb-trans"><h2>百時美施貴寶簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.</p>
<div class="lb-trans"><p>百時美施貴寶是一家全球生物製藥公司，總部位於新澤西州普林斯頓，專注於發現、開發和提供針對嚴重疾病的藥物。該公司的核心業務包括研究與開發、臨牀開發、製造和商業化多個治療領域的處方藥。BMS 專注於通過小分子和生物製劑推進腫瘤學、血液學、免疫學、心血管疾病和特殊領域的治療。</p>
</div><p>BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.</p>
<div class="lb-trans"><p>BMS 的市場產品組合和後期管線反映出對癌症和免疫介導疾病的強烈關注。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>閲讀更多</h2>
</div><ul>
<li>Five stocks we like better than Bristol Myers Squibb</li>
<li>Do not delete, read immediately</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>[No Brainer Gold Play]: “Show me a better investment.”</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過百時美施貴寶</li>
<li>請勿刪除，立即閲讀</li>
<li>崩盤已經開始（大多數人還未察覺）</li>
<li>警報：在 2026 年 1 月之前拋售這五隻股票！</li>
<li>[毫無疑問的黃金投資]：“給我看看更好的投資。”</li>
<li>投資者警報：微型 “3 美元人工智能奇蹟股票” 即將騰飛</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在百時美施貴寶嗎？</h2>
</div><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮百時美施貴寶之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場察覺之前...而百時美施貴寶並不在名單上。</p>
</div><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然百時美施貴寶目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

3Chopt Investment Partners LLC 出售了 36,326 股百時美施貴寶公司（Bristol Myers Squibb）的股票$BMY